Alligator Bioscience Select Sartorius Stedim Cellca as Cell Line Development Partner

Following the news release from Alligator Bioscience on 12th June 2017, Sartorius Stedim Cellca GmbH is delighted to partner with the innovative Swedish biotech company, Alligator Bioscience to support the pre-clinical development of their 4-1BB immuno-oncology antibody ATOR-1017.

ATOR-1017 is an agonistic antibody that activates the co-stimulatory receptor 4-1BB (also known as CD137) expressed on T cells in the tumor area. Activation of tumor-specific T cells leads to an anti-tumor immune attack and has the potential to give rise to a long-term protection from tumor growth. ATOR-1017 is being developed for treatment of metastasizing cancer. The properties of the antibody may direct the immune activation to the tumor area, which is believed to improve the risk-benefit profile.

Sartorius Stedim Cellca will provide the cell line development and upstream process to support the manufacture of clinical material for early stage clinical trials, utilizing the Cellca CHO Expression Platform.

Sartorius Stedim Cellca, Managing Director, Hugo De Wit commented “Our unique technology platform has consistently delivered high-yielding cell lines for our customers in our robust, easily scalable, fed-batch process. We look forward to supporting Alligator Bioscience during the pre-clinical development of their latest immuno-oncology antibody (ATOR-1017).”

To read the Alligator Bioscience news release please click here.

 

 

 

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.